Search

Background: Cold‐stored platelets are increasingly being used to treat bleeding. Differences in manufacturing processes and storage solutions can affect platelet quality and may influence the shelf life of cold‐stored platelets. PAS‐E and PAS‐F are approved platelet additive solutions (PAS) in Europe and Australia, or the United States respectively. Comparative data are required to facilitate international transferability of laboratory and clinical data. Study Design and Methods: Single apheresis platelets from matched donors (n = 8) were collected using the Trima apheresis platform and resuspended in either 40% plasma/60% PAS‐E or 40% plasma/60% PAS‐F. In a secondary study, platelets in PAS‐F were supplemented with sodium citrate, to match the concentration in PAS‐E. Components were refrigerated (2–6°C) and tested over 21 days. Results: Cold‐stored platelets in PAS‐F had a lower pH, a greater propensity to form visible (and micro‐) aggregates, and higher activation markers compared to PAS‐E. These differences were most pronounced during extended storage (14–21 days). While the functional capacity of cold‐stored platelets was similar, the PAS‐F group displayed minor improvements in ADP‐induced aggregation and TEG parameters (R‐time, angle). Supplementation of PAS‐F with 11 mM sodium citrate improved the platelet content, maintained the pH above specifications and prevented aggregate formation. Discussion: In vitro parameters were similar during short‐term cold storage of platelets in PAS‐E and PAS‐F. Storage in PAS‐F beyond 14 days resulted in poorer metabolic and activation parameters. However, the functional capacity was maintained, or even enhanced. The presence of sodium citrate may be an important constituent in PAS for extended cold storage of platelets. [ABSTRACT FROM AUTHOR]

Background: Cold‐stored platelets are increasingly being used to treat bleeding. Differences in manufacturing processes and storage solutions can affect platelet quality and may influence the shelf life of cold‐stored platelets. PAS‐E and PAS‐F are approved platelet additive solutions (PAS) in Europe and Australia, or the United States respectively. Comparative data are required to facilitate international transferability of laboratory and clinical data. Study Design and Methods: Single apheresis platelets from matched donors (n = 8) were collected using the Trima apheresis platform and resuspended in either 40% plasma/60% PAS‐E or 40% plasma/60% PAS‐F. In a secondary study, platelets in PAS‐F were supplemented with sodium citrate, to match the concentration in PAS‐E. Components were refrigerated (2–6°C) and tested over 21 days. Results: Cold‐stored platelets in PAS‐F had a lower pH, a greater propensity to form visible (and micro‐) aggregates, and higher activation markers compared to PAS‐E. These differences were most pronounced during extended storage (14–21 days). While the functional capacity of cold‐stored platelets was similar, the PAS‐F group displayed minor improvements in ADP‐induced aggregation and TEG parameters (R‐time, angle). Supplementation of PAS‐F with 11 mM sodium citrate improved the platelet content, maintained the pH above specifications and prevented aggregate formation. Discussion: In vitro parameters were similar during short‐term cold storage of platelets in PAS‐E and PAS‐F. Storage in PAS‐F beyond 14 days resulted in poorer metabolic and activation parameters. However, the functional capacity was maintained, or even enhanced. The presence of sodium citrate may be an important constituent in PAS for extended cold storage of platelets. [ABSTRACT FROM AUTHOR]